Verified Nov 2026
Batteries & E-Mobility
·

Stamford, Connecticut
·
Since 2013
Loxo@Lilly is a biopharmaceutical subsidiary of Eli Lilly and Company headquartered in Stamford, Connecticut. Founded in 2013 and acquired by Lilly in 2019, the company develops precision-targeted oncology medicines for patients with genomically defined cancers. With 500 to 1,000 employees and estimated annual revenue between $100 million and $250 million, it operates as Lilly's global precision oncology unit. The company has brought approved therapies to market, including treatments for NTRK fusion-positive and RET-mutant cancers.
Loxo@Lilly at a glance
Revenue
$100-250M
Est. band
Employees
500-1,000
Founded
2013
Headquarters
Stamford, Connecticut
Industries
Automotive
Electric Vehicles
Medical
Overview
Loxo@Lilly is a biopharmaceutical subsidiary of Eli Lilly and Company headquartered in Stamford, Connecticut. Founded in 2013 and acquired by Lilly in 2019, the company develops precision-targeted oncology medicines for patients with genomically defined cancers. With 500 to 1,000 employees and estimated annual revenue between $100 million and $250 million, it operates as Lilly's global precision oncology unit. The company has brought approved therapies to market, including treatments for NTRK fusion-positive and RET-mutant cancers.
At a glance
Attribute | Detail |
|---|---|
Founded | 2013 |
Headquarters | Stamford, Connecticut |
Employees | 500-1,000 |
Revenue | $100-250M (estimated) |
Primary capability | Batteries & E-Mobility |
What Loxo@Lilly makes
Loxo@Lilly specializes in discovery and development of targeted therapies, accelerated clinical trial execution, and precision medicine strategies that address unmet oncology needs in patients with specific gene abnormalities.
Company details
As a subsidiary of Eli Lilly and Company, the company combines a biotech operational model with the resources and infrastructure of a major global pharmaceutical corporation. Loxo@Lilly was founded in 2013, has an estimated 500-1,000 employees, and is headquartered in Stamford, Connecticut.
Frequently asked questions
What does Loxo@Lilly make?
Loxo@Lilly is a biopharmaceutical subsidiary of Eli Lilly and Company headquartered in Stamford, Connecticut. Founded in 2013 and acquired by Lilly in 2019, the company develops precision-targeted oncology medicines for patients with genomically defined cancers. With 500 to 1,000 employees and estimated annual revenue between $100 million and $250 million, it operates as Lilly's global precision oncology unit. The company has brought approved therapies to market, including treatments for NTRK fusion-positive and RET-mutant cancers.
Where is Loxo@Lilly headquartered?
Loxo@Lilly is headquartered in Stamford, Connecticut (281 Tresser Boulevard, Stamford, Connecticut, 06901).
When was Loxo@Lilly founded?
Loxo@Lilly was founded in 2013.
How big is Loxo@Lilly?
Loxo@Lilly has an estimated 500-1,000 employees, with revenue in the $100-250M range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
